Abatacept for immune-therapy heart inflammation in hospitalized adults
Part of Cancer, Heart & circulation clinical trials.
This Phase 3 trial tests abatacept to treat myocarditis (inflammation of the heart muscle) caused by immune checkpoint cancer medicines. It may help patients recover faster and safely manage this serious side effect while they are in the hospital.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can give informed consent (or your legal representative can).
- You were diagnosed with myocarditis, and you’re in the hospital at the time of randomization.
- You recently started an FDA-approved immune cancer medicine that can trigger myocarditis (within 6 months of diagnosis).
- Your myocarditis is being treated with high-dose steroid (solumedrol 1000 mg per day), or you will start it right away (within 24 hours of the first study medicine dose).
- Your blood tests show active heart injury (troponin at least 5 times the lab’s upper normal limit within the last 10 days).
- Recent bloodwork is acceptable and you can follow study rules, including pregnancy/contraception requirements if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether steroid medicine helps people hospitalized with suspected acute myocarditis (inflammation of the heart). Participants are randomly assigned to receive steroids or a placebo, and the trial looks at outcomes after the acute episode starts.
This trial tests whether giving steroids, immunoglobulins, or both can help people with a sudden, severe heart muscle inflammation (myocarditis) that causes shock or dangerous heart rhythms. The goal is to see if these treatments improve recovery compared to standard care.
This trial tests if non-steroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, help people with acute myocarditis (inflammation of the heart muscle) who are hospitalized but have normal heart function. It aims to see if these drugs can reduce inflammation and improve recovery.
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
This Phase 2 trial tests abatacept to improve a specific type of lung disease in children with common variable immunodeficiency (CVID). It aims to slow or reduce ongoing lung changes seen on CT scans while they continue their usual immune “replacement” therapy.
This trial tests whether tofacitinib, a pill that calms the immune system, can help people whose heart inflammation caused by cancer immunotherapy (called ICI) is not improving with steroid treatment. It may offer a new option for those with this rare but serious side effect.
Hear when a new Myocarditis Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.